Continue reading After 6 months of treatment, use of GLP-1 medications was associated with: Increased risk of androgenic alopecia Increased risk of non-scarring hair loss No significant change to the risk of telogen effluvium No significant change to the risk of alopecia areata After 12 months of treatment, use of GLP-1 medications was associated with: Increased risk of androgenic alopecia Increased risk of non-scarring hair loss Increased risk of telogen effluvium No significant change to the risk of alopecia areata Interestingly, no increased risk of alopecia areata was found, given that GLP-1 medications like semaglutide have been reported to be linked to this condition in case studies
Our GLP-1 Programs Semaglutide Program Semaglutide is FDA-approved for chronic weight management and has demonstrated an average of 15% total body weight loss in clinical trials over 68 weeks
Ipamorelin is a growth hormone secretagogue receptor agonist that has been shown in animal studies to have potent and specific effects on GH secretion while having very limited side effects [5]
Medical House Calls brings expert-level medical care directly to your door, eliminating the need for clinic visits, long wait times, or last-minute schedule changes
30,31,32 The correlations among astrocytes, microglial activation, neuroinflammation caused by gut microbiota and immune dysregulation in ASD patients are also involved in the pathological mechanism
